VYNE Therapeutics (VYNE) Competitors $0.92 0.00 (-0.20%) As of 10:57 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VYNE vs. KLRS, DTIL, VNRX, IFRX, VTVT, HOWL, CELU, CNTX, RNXT, and ANVSShould you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include Allovir (KLRS), Precision BioSciences (DTIL), VolitionRx (VNRX), InflaRx (IFRX), vTv Therapeutics (VTVT), Werewolf Therapeutics (HOWL), Celularity (CELU), Context Therapeutics (CNTX), RenovoRx (RNXT), and Annovis Bio (ANVS). These companies are all part of the "pharmaceutical products" industry. VYNE Therapeutics vs. Its Competitors Allovir Precision BioSciences VolitionRx InflaRx vTv Therapeutics Werewolf Therapeutics Celularity Context Therapeutics RenovoRx Annovis Bio Allovir (NASDAQ:KLRS) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, community ranking, dividends, analyst recommendations, institutional ownership, earnings and risk. Do analysts prefer KLRS or VYNE? VYNE Therapeutics has a consensus target price of $6.25, suggesting a potential upside of 579.35%. Given VYNE Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe VYNE Therapeutics is more favorable than Allovir.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allovir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00VYNE Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer KLRS or VYNE? VYNE Therapeutics received 36 more outperform votes than Allovir when rated by MarketBeat users. Likewise, 65.45% of users gave VYNE Therapeutics an outperform vote while only 0.00% of users gave Allovir an outperform vote. CompanyUnderperformOutperformAllovirOutperform VotesNo VotesUnderperform Votes3100.00% VYNE TherapeuticsOutperform Votes3665.45% Underperform Votes1934.55% Which has more risk and volatility, KLRS or VYNE? Allovir has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Which has stronger valuation & earnings, KLRS or VYNE? Allovir has higher earnings, but lower revenue than VYNE Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllovirN/AN/AN/AN/AN/AVYNE Therapeutics$605K23.13-$28.45M-$0.99-0.93 Do institutionals & insiders believe in KLRS or VYNE? 66.1% of Allovir shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 32.1% of Allovir shares are held by company insiders. Comparatively, 4.8% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer KLRS or VYNE? In the previous week, Allovir had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 3 mentions for Allovir and 2 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 0.44 beat Allovir's score of 0.25 indicating that VYNE Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Allovir Neutral VYNE Therapeutics Neutral Is KLRS or VYNE more profitable? Allovir has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -6,896.55%. Allovir's return on equity of 0.00% beat VYNE Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AllovirN/A N/A N/A VYNE Therapeutics -6,896.55%-43.73%-38.55% SummaryVYNE Therapeutics beats Allovir on 9 of the 14 factors compared between the two stocks. Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYNE vs. The Competition Export to ExcelMetricVYNE TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.99M$6.93B$5.60B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-1.078.8527.2320.02Price / Sales23.13256.44417.65154.33Price / CashN/A65.8538.2534.64Price / Book0.146.617.124.70Net Income-$28.45M$143.93M$3.23B$247.97M7 Day Performance-8.00%3.84%2.74%2.64%1 Month Performance-26.40%11.14%8.94%6.39%1 Year Performance-57.21%4.35%31.59%13.95% VYNE Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYNEVYNE Therapeutics2.514 of 5 stars$0.92-0.2%$6.25+579.3%-59.7%$13.99M$605K-1.0730Short Interest ↑KLRSAllovirN/A$3.00+3.4%N/AN/A$56.11MN/A0.00110Analyst DowngradeDTILPrecision BioSciences4.2152 of 5 stars$5.04+4.3%$47.00+832.5%-57.8%$55.88M$51.14M84.01200VNRXVolitionRx2.0538 of 5 stars$0.53+5.2%$3.75+608.9%-23.6%$54.50M$1.31M-1.4780News CoverageAnalyst UpgradeHigh Trading VolumeIFRXInflaRx3.563 of 5 stars$0.81+0.9%$6.60+714.8%-46.6%$54.38M$129.75K-0.7560Positive NewsShort Interest ↑Analyst RevisionGap UpVTVTvTv Therapeutics1.7279 of 5 stars$16.91+6.4%$35.50+109.9%-9.2%$54.03M$17K-3.739HOWLWerewolf Therapeutics3.9512 of 5 stars$1.20-0.8%$8.33+594.4%-61.6%$53.85M$1.14M-0.7840Positive NewsGap UpCELUCelularity0.5434 of 5 stars$2.24+6.2%N/A-46.1%$53.65M$54.22M-0.85220News CoverageGap UpCNTXContext Therapeutics3.1065 of 5 stars$0.59+1.9%$6.00+920.4%-69.7%$52.75MN/A-0.657Positive NewsGap UpRNXTRenovoRx2.9753 of 5 stars$1.42+1.4%$7.00+393.0%+29.5%$51.93M$240K-2.496Short Interest ↓High Trading VolumeANVSAnnovis Bio2.1276 of 5 stars$2.63+11.9%$34.75+1,221.3%-58.5%$51.25MN/A-0.593News CoverageAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies KLRS Competitors DTIL Competitors VNRX Competitors IFRX Competitors VTVT Competitors HOWL Competitors CELU Competitors CNTX Competitors RNXT Competitors ANVS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VYNE) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VYNE Stock Free VYNE Stock Alerts